Skip to main content
. 2021 Aug 18;12(2):907–923. doi: 10.1016/j.apsb.2021.08.016

Figure 7.

Figure 7

In vivo biosafety evaluation of different treatment approaches. (A) Body weight variations (B) pro-inflammatory cytokine levels (C) organ coefficients (D) complement C3 (E) ALP (F) ALT (G) AST (H) BUN, and (I) GRE in plasma collected from the mice with the treatment of TFENs via i.v. and oral routes. (J) Histological analysis of the five main organs from the mice with the treatment of TFENs via i.v. and oral routes (scale bar = 100 μm). Each point represents the mean ± SEM (n = 3). ∗P < 0.05, ∗∗P < 0.01. ns, no significance.